Frontier Biotechnologies(SH:688221) Shang Hai Zheng Quan Bao·2025-10-09 18:55Core Viewpoint - The company has successfully held its second extraordinary general meeting of shareholders in 2025, where key resolutions regarding the 2025 Restricted Stock Incentive Plan were approved, including the authorization for the board to handle related matters [2][3][10]. Group 1: Meeting Details - The extraordinary general meeting was held on October 9, 2025, at the Nanjing Jiayue Yinh Lake Hotel [2]. - A total of 6 out of 7 current directors attended the meeting, along with all 3 supervisors and the board secretary [2][3]. - All resolutions presented at the meeting were passed with more than two-thirds of the voting rights held by attending shareholders [3]. Group 2: Incentive Plan Approval - The board approved the "2025 Restricted Stock Incentive Plan" and its summary, along with the implementation assessment management measures [3][10]. - The board authorized the granting of 4.25 million shares of restricted stock to 27 incentive objects at a price of 8.56 yuan per share, effective from October 9, 2025 [12][24][25]. Group 3: Insider Trading Self-Examination - The company conducted a self-examination regarding insider trading related to the 2025 Restricted Stock Incentive Plan, confirming that no insider trading occurred during the specified period [4][8]. - Three incentive objects were found to have traded company stock during the self-examination period, but these trades were based on public market information and did not involve insider information [7][8]. Group 4: Legal Compliance and Opinions - The company ensured that the meeting and the resolutions complied with relevant laws and regulations, as confirmed by the witnessing lawyers [3][10]. - The legal opinion concluded that all necessary approvals and authorizations for the stock grant had been obtained, and the conditions for granting the stock had been met [47].